Genes and other biological markers are rapidly being identified that can provide presymptomatic estimates of risk for the eventual development of late-onset diseases. There is widespread public interest in obtaining risk information, particularly as treatments are developed to slow or prevent the onset of degenerative diseases. Many of the recently discovered gene markers are not deterministic genes, but rather susceptibility genes that interact with other, as yet unidentified genes, and with factors such as age, gender, race, family history and environmental exposures. Therefore genotyping individuals for susceptibility genes will require different protocols for providing risk assessment and counseling than those that have been used with deterministic genes. With few restrictions on the marketing and utilization of such tests, their usage may soon increase. Yet, there are almost no data available to understand who (e.g. age, gender, race) would seek susceptibility risk information once it is available; and why they would do so (e.g. to alleviate anxiety, to prepare financially). Nor is there information on the benefits or negative consequences of providing susceptibility risk information that could guide rational clinical decisions or public policy. In its first finding period, the REVEAL Study created original educational and counseling protocols, and enrolled over 150 adult children of patients with Alzheimer's disease (AD) into a randomized clinical trial to examine (1) the characteristics of those persons who sought risk assessment with genetic susceptibility testing, including APOE genotype disclosure and (2) the impact of this disclosure. In the next funding period of the Study (REVEAL II), we will include siblings of patients with AD in the study, and will randomize adult children or siblings to the current Extended Protocol or to a new Condensed Protocol that will more closely minor clinical interactions that could be implemented on a large scale. We will also explore how the impact of genetic susceptibility testing with APOE disclosure varies between younger and older relatives, and between relatives of African American and European American patients with AD. REVEAL II will take place at four clinical centers of care (Boston University, Cornell University, Case Western University and Howard University). Risk assessment using genetic susceptibility testing with APOE genotyping and disclosure, because of its inherent uncertainties, is an ideal model to develop new guidelines for whether and bow best to use susceptibility gene markers in this and other diseases where such markers are, or will be, available in the near future.
| Christensen, Kurt D; Uhlmann, Wendy R; Roberts, J Scott et al. (2018) A randomized controlled trial of disclosing genetic risk information for Alzheimer disease via telephone. Genet Med 20:132-141 |
| Uhlmann, Wendy R; Roberts, J Scott (2018) Ethical issues in neurogenetics. Handb Clin Neurol 147:23-36 |
| Ridge, Perry G; Wadsworth, Mark E; Miller, Justin B et al. (2018) Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping. Alzheimers Dement 14:514-519 |
| Guan, Yue; Roter, Debra L; Wolff, Jennifer L et al. (2018) The impact of genetic counselors' use of facilitative strategies on cognitive and emotional processing of genetic risk disclosure for Alzheimer's disease. Patient Educ Couns 101:817-823 |
| Han, Paul K J; Umstead, Kendall L; Bernhardt, Barbara A et al. (2017) A taxonomy of medical uncertainties in clinical genome sequencing. Genet Med 19:918-925 |
| Guan, Yue; Roter, Debra L; Erby, Lori H et al. (2017) Disclosing genetic risk of Alzheimer's disease to cognitively impaired patients and visit companions: Findings from the REVEAL Study. Patient Educ Couns 100:927-935 |
| Christensen, Kurt D; Roberts, J Scott; Whitehouse, Peter J et al. (2016) Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial. Ann Intern Med 164:155-63 |
| Baptista, Natalie M; Christensen, Kurt D; Carere, Deanna Alexis et al. (2016) Adopting genetics: motivations and outcomes of personal genomic testing in adult adoptees. Genet Med 18:924-32 |
| Olfson, Emily; Hartz, Sarah; Carere, Deanna Alexis et al. (2016) Implications of Personal Genomic Testing for Health Behaviors: The Case of Smoking. Nicotine Tob Res 18:2273-2277 |
| Lebo, Matthew S; Sutti, Sheila; Green, Robert C (2016) ""Big Data"" Gets Personal. Sci Transl Med 8:322fs3-3fs3 |
Showing the most recent 10 out of 107 publications
